Daratumumab in Immune-mediated Thrombotic Thrombocytopenic Purpura

计划入组 40 人 · 首次发布于 2026 年 4 月 7 日

A Pilot Study of Efgartigimod for Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

计划入组 15 人 · 首次发布于 2025 年 2 月 17 日

Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura

计划入组 51 人 · 首次发布于 2022 年 7 月 21 日

Caplacizumab(Cablivi)

GPVI inhibitors (thrombotic disorders)

small molecule SLC transporter modulator (immune-mediated disease)

US THROMBOTIC MICROANGIOPATHY ALLIANCE

United States

AC Immune

Switzerland

Immune Biosolutions Inc

Canada

TargED Biopharmaceuticals Initiates Phase 1 Trial of TGD001 for Thrombotic Disorders

Sanofi Secures Chinese Approval for Two Rare Blood Disorder Therapies Qfitlia and Cablivi

Global Thrombocytopenia Clinical Trials Market Sees Significant Growth in 2025